

**Question for written answer E-001376/2022**  
**to the Commission**  
Rule 138  
**Dino Giarrusso (NI)**

Subject: Redundancies at Catania Pfizer plant

Using a workforce reduction procedure (under Article 24 of Law No 223/1991), the Catania Pfizer plant has stated that it is laying off 130 workers, including those with management, office and production roles. In addition to these redundancies, the company plans not to renew the contracts of about 100 temporary workers.

Pfizer is a leading pharmaceutical company that has earned huge profits in recent years thanks to massive orders both nationally and internationally. The agreement with the Commission has allowed the company to invest heavily in research, allowing it to earn additional profits from subsequent discoveries.

In view of the above,:

1. Why is it that the Commission, which has concluded agreements for billions of euros with this company, has never asked for guarantees regarding the future of its European plants and has not considered stepping in to mediate?
2. What instruments can the Commission use to ensure that discussions on the laying-off of hundreds of workers are reopened, hosting a round table or refusing to have any further relationship with Pfizer?